A single patient with complex regional pain syndrome (CRPS) that did not respond to standard treatments experienced substantial pain relief and improved function after taking psilocybin. This case suggests psilocybin may be a promising therapy for refractory CRPS, but more research is needed to determine its effectiveness and the best dosage for chronic pain.
A systematic review of 28 studies on psilocybin for chronic pain management found that most evidence is low or very low quality (76.2% of studies). Several moderate-to-low-quality studies used a 0.14 mg/kg dosing protocol. The results suggest promise for psilocybin in relieving chronic pain, but methodological weaknesses and a lack of high-quality evidence highlight the need for further research with standardized protocols.
A 41-year-old fully vaccinated woman with Long-COVID syndrome experienced significant symptom relief after self-medicating with psilocybin and MDMA. Long-COVID, a condition persisting after the acute phase of COVID-19, currently lacks effective holistic treatments. This case suggests potential benefit from these substances, but further research is required to evaluate their safety and efficacy.
COVID-19 is a highly contagious respiratory illness caused by the SARS-CoV-2 virus, first identified in Wuhan, China in December 2019, and has since spread globally.